8-K Announcements
6Material company update
Mar 26, 2026·SEC
Material company update
Mar 12, 2026·SEC
Material company update
Feb 9, 2026·SEC
Enanta Pharmaceuticals, Inc.(ENTA)Earnings, Financials & Key Ratios
ENTA•NASDAQ
$14.48
$420M mkt cap·Price updated May 6, 2026
AboutEnanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.Show more
- Revenue$65M-3.4%
- EBITDA-$80M+32.8%
- Net Income-$82M+29.4%
- EPS (Diluted)-3.84+29.9%
- Gross Margin92.98%-7.0%
- EBITDA Margin-122.86%+30.4%
- Operating Margin-130.65%+27.4%
- Net Margin-125.36%+26.9%
- ROE-84.63%-26.0%
- ROIC-23.23%+14.6%
- Debt/Equity3.11+77.0%
- Interest Coverage-11.11+0.1%
ENTA Key Insights
Enanta Pharmaceuticals, Inc. (ENTA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗High debt to equity ratio of 3.1x
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Sales declining 11.8% over 5 years
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ENTA Price & Volume
Enanta Pharmaceuticals, Inc. (ENTA) stock price & volume — 10-year historical chart
Loading chart...
ENTA Growth Metrics
Enanta Pharmaceuticals, Inc. (ENTA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-8.62%
5 Years-11.81%
3 Years-8.82%
TTM0.58%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM31.82%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM35.35%
Return on Capital
10 Years-11.41%
5 Years-31.87%
3 Years-33.8%
Last Year-30.96%
ENTA Recent Earnings
Enanta Pharmaceuticals, Inc. (ENTA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 5/12 qtrs (42%)
Q1 2026Latest
Feb 9, 2026EPS
$0.42
Est $0.54
+22.2%
Revenue
$19M
Est $16M
+17.0%
Q4 2025
Nov 17, 2025EPS
$0.87
Est $1.13
+23.0%
Revenue
$15M
Est $16M
-5.3%
Q3 2025
Aug 11, 2025EPS
$0.85
Est $1.25
+32.0%
Revenue
$18M
Est $16M
+14.7%
Q2 2025
May 12, 2025EPS
$1.06
Est $1.04
-1.9%
Revenue
$15M
Est $16M
-6.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 9, 2026 | $0.42vs $0.54+22.2% | $19Mvs $16M+17.0% |
| Q4 2025 | Nov 17, 2025 | $0.87vs $1.13+23.0% | $15Mvs $16M-5.3% |
| Q3 2025 | Aug 11, 2025 | $0.85vs $1.25+32.0% | $18Mvs $16M+14.7% |
| Q2 2025 | May 12, 2025 | $1.06vs $1.04-1.9% | $15Mvs $16M-6.5% |
Based on last 12 quarters of dataView full earnings history →
ENTA Peer Comparison
Enanta Pharmaceuticals, Inc. (ENTA) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACHV | 240.82M | 4.56 | -3.65 | -196.68% | 0.70 | |||
 AGIO | 1.62B | 27.21 | -3.82 | 48.03% | -6.4% | -34.11% | 0.05 | |
 ARQT | 2.89B | 23.42 | -180.15 | 91.34% | -4.29% | -8.52% | 0.03 | |
 PRTA | 602.39M | 11.19 | -2.47 | -92.84% | -25.21% | -73% | 0.05 | |
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 RCUS | 2.62B | 26.06 | -7.92 | -4.26% | -156.36% | -68.97% | 0.16 | |
 IMVT | 5.66B | 27.84 | -10.20 | -47.07% | 0.00 | |||
 ALNY | 40.18B | 301.11 | 129.23 | 65.19% | 13.46% | 98.29% | 1.16% | 1.62 |
Compare ENTA vs Peers
Enanta Pharmaceuticals, Inc. (ENTA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ENTA Income Statement
Enanta Pharmaceuticals, Inc. (ENTA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 102.81M | 206.63M | 205.2M | 122.47M | 97.07M | 86.16M | 79.2M | 67.64M | 65.32M | 66.98M |
| Revenue Growth % | 16.48% | 100.97% | -0.69% | -40.31% | -20.74% | -11.24% | -8.07% | -14.61% | -3.42% | 0.58% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.59M | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | 7.02% | - |
| Gross Profit | 102.81M▲ 0% | 206.63M▲ 101.0% | 205.2M▼ 0.7% | 122.47M▼ 40.3% | 97.07M▼ 20.7% | 86.16M▼ 11.2% | 79.2M▼ 8.1% | 67.64M▼ 14.6% | 60.74M▼ 10.2% | 48.37M▲ 0% |
| Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 92.98% | 72.21% |
| Gross Profit Growth % | 16.48% | 100.97% | -0.69% | -40.31% | -20.74% | -11.24% | -8.07% | -14.61% | -10.2% | - |
| Operating Expenses | 78.2M | 118.3M | 168.46M | 164.11M | 206.65M | 210M | 216.41M | 189.33M | 146.09M | 140.04M |
| OpEx % of Revenue | 76.06% | 57.25% | 82.1% | 134% | 212.88% | 243.74% | 273.23% | 279.92% | 223.63% | - |
| Selling, General & Admin | 20.75M | 23.44M | 26.25M | 27.36M | 32.54M | 45.48M | 52.89M | 57.85M | 43.93M | 40.1M |
| SG&A % of Revenue | 20.18% | 11.34% | 12.79% | 22.34% | 33.52% | 52.79% | 66.77% | 85.53% | 67.25% | - |
| Research & Development | 57.45M | 94.86M | 142.21M | 136.76M | 174.11M | 164.52M | 163.52M | 131.48M | 106.74M | 99.94M |
| R&D % of Revenue | 55.88% | 45.91% | 69.31% | 111.66% | 179.36% | 190.95% | 206.46% | 194.39% | 163.4% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.59M | 0 |
| Operating Income | 24.61M▲ 0% | 88.33M▲ 258.9% | 36.74M▼ 58.4% | -41.64M▼ 213.3% | -109.57M▼ 163.1% | -123.84M▼ 13.0% | -137.21M▼ 10.8% | -121.69M▲ 11.3% | -85.35M▲ 29.9% | -73.06M▲ 0% |
| Operating Margin % | 23.94% | 42.75% | 17.9% | -34% | -112.88% | -143.74% | -173.23% | -179.92% | -130.65% | -109.08% |
| Operating Income Growth % | -20.19% | 258.85% | -58.41% | -213.34% | -163.15% | -13.02% | -10.79% | 11.31% | 29.86% | - |
| EBITDA | 26.75M | 90.85M | 40M | -37.99M | -106.24M | -120.87M | -134.84M | -119.36M | -80.26M | -69.36M |
| EBITDA Margin % | 26.02% | 43.97% | 19.49% | -31.02% | -109.44% | -140.29% | -170.24% | -176.47% | -122.86% | -103.56% |
| EBITDA Growth % | -17.69% | 239.6% | -55.97% | -195% | -179.61% | -13.77% | -11.55% | 11.48% | 32.76% | 35.64% |
| D&A (Non-Cash Add-back) | 2.14M | 2.52M | 3.26M | 3.64M | 3.33M | 2.97M | 2.37M | 2.34M | 5.09M | 3.7M |
| EBIT | 24.61M | 88.33M | 36.74M | -41.64M | -107.58M | -122.19M | -125.85M | -106.85M | -75.87M | -63.95M |
| Net Interest Income | 2.49M | 4.85M | 8.82M | 6.47M | 2.02M | 1.57M | 6.21M | 3.83M | 1.8M | 302K |
| Interest Income | 2.53M | 0 | 8.82M | 6.47M | 2.02M | 1.57M | 11.36M | 14.77M | 9.48M | 9.1M |
| Interest Expense | 40K | 4.85M | 0 | 0 | 0 | 0 | 5.15M | 10.94M | 7.68M | 8.8M |
| Other Income/Expense | 2.33M | 4.79M | 8.82M | 6.62M | 1.99M | 1.66M | 6.21M | 3.9M | 1.8M | 302K |
| Pretax Income | 26.95M▲ 0% | 93.12M▲ 245.6% | 45.56M▼ 51.1% | -35.02M▼ 176.9% | -107.58M▼ 207.2% | -122.19M▼ 13.6% | -131M▼ 7.2% | -117.79M▲ 10.1% | -83.55M▲ 29.1% | -72.76M▲ 0% |
| Pretax Margin % | 26.21% | 45.07% | 22.2% | -28.59% | -110.82% | -141.82% | -165.39% | -174.15% | -127.9% | -108.62% |
| Income Tax | 9.24M | 21.16M | -826K | 1.15M | -28.58M | -433K | 2.82M | -1.74M | -1.66M | -1.22M |
| Effective Tax Rate % | 34.28% | 22.73% | -1.81% | -3.28% | 26.57% | 0.35% | -2.15% | 1.48% | 1.99% | 1.68% |
| Net Income | 17.71M▲ 0% | 71.96M▲ 306.3% | 46.38M▼ 35.5% | -36.17M▼ 178.0% | -79M▼ 118.4% | -121.75M▼ 54.1% | -133.82M▼ 9.9% | -116.05M▲ 13.3% | -81.89M▲ 29.4% | -71.54M▲ 0% |
| Net Margin % | 17.23% | 34.82% | 22.6% | -29.53% | -81.38% | -141.31% | -168.95% | -171.58% | -125.36% | -106.8% |
| Net Income Growth % | -18.26% | 306.3% | -35.54% | -177.98% | -118.41% | -54.13% | -9.91% | 13.28% | 29.43% | 31.82% |
| Net Income (Continuing) | 17.71M | 71.96M | 46.38M | -36.17M | -79M | -121.75M | -133.82M | -116.05M | -81.89M | -59.6M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.91▲ 0% | 3.48▲ 282.4% | 2.21▼ 36.5% | -1.81▼ 181.9% | -3.92▼ 116.6% | -5.91▼ 50.8% | -6.38▼ 8.0% | -5.48▲ 14.1% | -3.84▲ 29.9% | -2.49▲ 0% |
| EPS Growth % | -19.47% | 282.42% | -36.49% | -181.9% | -116.57% | -50.77% | -7.95% | 14.11% | 29.93% | 35.35% |
| EPS (Basic) | 0.93 | 3.48 | 2.37 | -1.81 | -3.92 | -5.91 | -6.38 | -5.48 | -3.84 | - |
| Diluted Shares Outstanding | 19.41M | 20.65M | 20.97M | 19.94M | 20.17M | 20.6M | 20.97M | 21.16M | 21.34M | 28.75M |
| Basic Shares Outstanding | 19.07M | 20.65M | 19.58M | 19.94M | 20.17M | 20.6M | 20.97M | 21.16M | 21.34M | 28.75M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ENTA Balance Sheet
Enanta Pharmaceuticals, Inc. (ENTA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 237.82M | 380.39M | 401.85M | 436.84M | 319.02M | 311.71M | 422.79M | 299.85M | 204.34M | 198.68M |
| Cash & Short-Term Investments | 223.67M | 308.73M | 335.24M | 386.65M | 244M | 249.23M | 369.91M | 248.19M | 188.86M | 185.85M |
| Cash Only | 65.67M | 63.9M | 51.23M | 87.13M | 57.21M | 43.99M | 85.39M | 37.23M | 32.3M | 37.44M |
| Short-Term Investments | 157.99M | 244.83M | 284.01M | 299.52M | 186.8M | 205.24M | 284.52M | 210.95M | 156.57M | 148.41M |
| Accounts Receivable | 10.61M | 67.2M | 51.31M | 23.49M | 60.83M | 49.04M | 39.62M | 38.65M | 6.88M | 8.49M |
| Days Sales Outstanding | 37.68 | 118.72 | 91.27 | 70.01 | 228.73 | 207.73 | 182.57 | 208.55 | 38.45 | 87.68 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 3.54M | 4.45M | 0 | 26.7M | 0 | 13.45M | 0 | 608K | 8.59M | 4.34M |
| Total Non-Current Assets | 88.82M | 33.84M | 87.98M | 53.95M | 121.84M | 68.88M | 39.48M | 76.8M | 76.4M | 130.82M |
| Property, Plant & Equipment | 8.05M | 8.37M | 10.93M | 15.62M | 10.65M | 29.75M | 34.71M | 73.35M | 72.94M | 71.31M |
| Fixed Asset Turnover | 12.77x | 24.67x | 18.78x | 7.84x | 9.11x | 2.90x | 2.28x | 0.92x | 0.90x | 0.91x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 70.04M | 16.39M | 65.01M | 33.24M | 109.02M | 33.25M | 3.97M | 3.36M | 3.36M | 6.72M |
| Other Non-Current Assets | 608K | 700K | 700K | 92K | 92K | 696K | 803K | 94K | 92K | 63.15M |
| Total Assets | 326.64M▲ 0% | 414.23M▲ 26.8% | 489.83M▲ 18.3% | 490.79M▲ 0.2% | 440.86M▼ 10.2% | 380.59M▼ 13.7% | 462.27M▲ 21.5% | 376.65M▼ 18.5% | 280.73M▼ 25.5% | 329.5M▲ 0% |
| Asset Turnover | 0.31x | 0.50x | 0.42x | 0.25x | 0.22x | 0.23x | 0.17x | 0.18x | 0.23x | 0.22x |
| Asset Growth % | 16.13% | 26.82% | 18.25% | 0.2% | -10.17% | -13.67% | 21.46% | -18.52% | -25.47% | -77.38% |
| Total Current Liabilities | 20.98M | 16.02M | 22.61M | 24.16M | 36.17M | 29.83M | 62.79M | 57.53M | 48.55M | 44.73M |
| Accounts Payable | 3.71M | 4.75M | 6.69M | 5.74M | 9.54M | 6M | 4.1M | 8M | 1.95M | 1.89M |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | 155.04 | - |
| Short-Term Debt | 0 | 0 | 0 | 4.26M | 4.2M | 2.89M | 35.08M | 34.46M | 33.86M | 3.29M |
| Deferred Revenue (Current) | 9.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 9.22M | 0 | 0 | 9.38M | 12.13M | 11.61M | 0 | 0 | -3.15M | 39.56M |
| Current Ratio | 11.33x | 23.74x | 17.77x | 18.08x | 8.82x | 10.45x | 6.73x | 5.21x | 4.21x | 4.21x |
| Quick Ratio | 11.33x | 23.74x | 17.77x | 18.08x | 8.82x | 10.45x | 6.73x | 5.21x | 4.21x | 4.21x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 87.68 |
| Total Non-Current Liabilities | 3.98M | 4.52M | 4.73M | 11.05M | 5.26M | 29.43M | 182.75M | 190.3M | 167.46M | 158.18M |
| Long-Term Debt | 0 | 0 | 0 | 1.48M | 1.51M | 1.42M | 160.85M | 136.13M | 112.44M | 53.78M |
| Capital Lease Obligations | 379K | 293K | 200K | 3.84M | 1.13M | 22.37M | 21.24M | 53.94M | 54.76M | 220.73M |
| Deferred Tax Liabilities | 1.18M | 1.79M | 1.75M | 4.66M | 2.07M | 5.18M | 7.56M | 0 | 0 | 0 |
| Other Non-Current Liabilities | 3.6M | 4.23M | 4.53M | 1.08M | 558K | 454K | 663K | 231K | 260K | 105.16M |
| Total Liabilities | 24.96M | 20.55M | 27.34M | 35.21M | 41.43M | 59.26M | 245.54M | 247.84M | 216.01M | 202.91M |
| Total Debt | 458K | 293K | 200K | 9.58M | 6.83M | 26.69M | 222.44M | 226.06M | 201.06M | 57.07M |
| Net Debt | -65.22M | -63.61M | -51.03M | -77.55M | -50.37M | -17.31M | 137.05M | 188.82M | 168.76M | 19.63M |
| Debt / Equity | 0.00x | 0.00x | 0.00x | 0.02x | 0.02x | 0.08x | 1.03x | 1.75x | 3.11x | 3.11x |
| Debt / EBITDA | 0.02x | 0.00x | 0.01x | - | - | - | - | - | - | -0.82x |
| Net Debt / EBITDA | -2.44x | -0.70x | -1.28x | - | - | - | - | - | - | -0.28x |
| Interest Coverage | 615.35x | 18.20x | - | - | - | - | -26.65x | -11.12x | -11.11x | -7.27x |
| Total Equity | 301.68M▲ 0% | 393.68M▲ 30.5% | 462.49M▲ 17.5% | 455.58M▼ 1.5% | 399.43M▼ 12.3% | 321.33M▼ 19.6% | 216.74M▼ 32.6% | 128.81M▼ 40.6% | 64.72M▼ 49.8% | 126.59M▲ 0% |
| Equity Growth % | 11.76% | 30.5% | 17.48% | -1.49% | -12.33% | -19.55% | -32.55% | -40.57% | -49.76% | -127% |
| Book Value per Share | 15.54 | 19.06 | 22.06 | 22.85 | 19.80 | 15.60 | 10.34 | 6.09 | 3.03 | 4.40 |
| Total Shareholders' Equity | 301.68M | 393.68M | 462.49M | 455.58M | 399.43M | 321.33M | 216.74M | 128.81M | 64.72M | 126.59M |
| Common Stock | 191K | 194K | 197K | 201K | 202K | 208K | 211K | 212K | 214K | 290K |
| Retained Earnings | 45.36M | 117.36M | 163.74M | 127.57M | 48.58M | -73.18M | -207M | -323.04M | -404.93M | -416.87M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -112K | -398K | 146K | 844K | -382K | -3.72M | -1.17M | 302K | -339K | -329K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ENTA Cash Flow Statement
Enanta Pharmaceuticals, Inc. (ENTA) cash flow — operating, investing & free cash flow history
| Line item | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 52.65M | 29.22M | 71.42M | 7.09M | -70M | -84.78M | -103.15M | -78.76M | -19.27M | -19.27M |
| Operating CF Margin % | 51.21% | 14.14% | 34.8% | 5.79% | -72.11% | -98.4% | -130.24% | -116.45% | -29.5% | - |
| Operating CF Growth % | 47.04% | -44.5% | 144.41% | -90.08% | -1087.53% | -21.12% | -21.67% | 23.64% | 75.53% | 339.3% |
| Net Income | 17.71M | 71.96M | 46.38M | -36.17M | -79M | -121.75M | -133.82M | -116.05M | -81.89M | -71.54M |
| Depreciation & Amortization | 2.14M | 2.52M | 3.26M | 3.64M | 3.33M | 2.97M | 2.37M | 2.34M | 5.09M | 4.95M |
| Stock-Based Compensation | 13.07M | 15.85M | 19.23M | 19.57M | 20.99M | 26.97M | 28.22M | 26.8M | 18.57M | 16.71M |
| Deferred Taxes | -1.65M | 1.86M | -3.14M | 10.61M | 345K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -581K | -1.17M | -5.8M | -3.47M | -1.98M | 242K | -7.95M | 1.02M | -946K | -4.08M |
| Working Capital Changes | 21.97M | -61.79M | 11.49M | 12.9M | -13.69M | 6.79M | 8.02M | 7.13M | 39.91M | 39.8M |
| Change in Receivables | 2.23M | -56.59M | 15.89M | 27.82M | -24.3M | 11.79M | 9.42M | 973K | 31.76M | 31.67M |
| Change in Inventory | 18.63M | -6.42M | -6.48M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 633K | 1.32M | 1.79M | -883K | 3.77M | -4.63M | -1.15M | -414K | -1.31M | -1.21M |
| Cash from Investing | -4.57M | -35.4M | -86.66M | 19.83M | 36.99M | 54.9M | -53.58M | 58.23M | 40.35M | -75.85M |
| Capital Expenditures | -2.51M | -2.98M | -5.42M | -1.45M | -750K | -2.13M | -9.06M | -17.95M | -12.9M | -4.29M |
| CapEx % of Revenue | 2.44% | 1.44% | 2.64% | 1.18% | 0.77% | 2.47% | 11.44% | 26.54% | 19.74% | - |
| Acquisitions | 0 | 0 | 86.66M | 0 | -37.74M | -54.9M | 44.52M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -2.07M | -32.42M | 0 | 0 | 37.74M | 54.9M | -44.52M | 0 | 0 | 0 |
| Cash from Financing | 1.02M | 4.41M | 2.57M | 8.98M | 3.08M | 20.03M | 198.13M | -27.63M | -26.62M | 42.5M |
| Debt Issued (Net) | -73K | -79K | -86K | 0 | 0 | 0 | 199.68M | -27.48M | -26.49M | -26.49M |
| Equity Issued (Net) | 0 | 0 | 0 | 0 | 1000K | 1000K | 1000K | 147K | 145K | 51K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.09M | 4.49M | 2.66M | 8.98M | -534K | -1.23M | -3.76M | -294K | -277K | 68.94M |
| Net Change in Cash | 49.1M▲ 0% | -1.77M▼ 103.6% | -12.67M▼ 614.7% | 35.9M▲ 383.3% | -29.93M▼ 183.4% | -9.85M▲ 67.1% | 41.39M▲ 520.2% | -48.16M▼ 216.3% | -5.54M▲ 88.5% | -47.52M▲ 0% |
| Free Cash Flow | 50.15M▲ 0% | 26.24M▼ 47.7% | 66M▲ 151.5% | 5.64M▼ 91.5% | -70.75M▼ 1353.7% | -86.91M▼ 22.8% | -112.21M▼ 29.1% | -96.71M▲ 13.8% | -32.17M▲ 66.7% | -18.46M▲ 0% |
| FCF Margin % | 48.77% | 12.7% | 32.16% | 4.61% | -72.88% | -100.87% | -141.67% | -142.99% | -49.24% | -27.57% |
| FCF Growth % | 61.39% | -47.68% | 151.54% | -91.45% | -1353.69% | -22.84% | -29.12% | 13.81% | 66.74% | 80.86% |
| FCF per Share | 2.58 | 1.27 | 3.15 | 0.28 | -3.51 | -4.22 | -5.35 | -4.57 | -1.51 | -1.51 |
| FCF Conversion (FCF/Net Income) | 2.97x | 0.41x | 1.54x | -0.20x | 0.89x | 0.70x | 0.77x | 0.68x | 0.24x | 0.26x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 1.99M | 11.71M | 8.79M | 3.31M |
| Taxes Paid | 1.59M | 26.09M | 12.67M | 105K | 32K | 0 | 4.9M | 241K | 109K | 0 |
ENTA Key Ratios
Enanta Pharmaceuticals, Inc. (ENTA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 6.2% | 20.7% | 10.84% | -7.88% | -18.48% | -33.78% | -49.74% | -67.17% | -84.63% | -56.51% |
| Return on Invested Capital (ROIC) | 7.53% | 23.39% | 7.43% | -7.91% | -22.61% | -28.44% | -31.29% | -27.19% | -23.23% | -23.23% |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 92.98% | 72.21% |
| Net Margin | 17.23% | 34.82% | 22.6% | -29.53% | -81.38% | -141.31% | -168.95% | -171.58% | -125.36% | -106.8% |
| Debt / Equity | 0.00x | 0.00x | 0.00x | 0.02x | 0.02x | 0.08x | 1.03x | 1.75x | 3.11x | 3.11x |
| Interest Coverage | 615.35x | 18.20x | - | - | - | - | -26.65x | -11.12x | -11.11x | -7.27x |
| FCF Conversion | 2.97x | 0.41x | 1.54x | -0.20x | 0.89x | 0.70x | 0.77x | 0.68x | 0.24x | 0.26x |
| Revenue Growth | 16.48% | 100.97% | -0.69% | -40.31% | -20.74% | -11.24% | -8.07% | -14.61% | -3.42% | 0.58% |
ENTA SEC Filings & Documents
Enanta Pharmaceuticals, Inc. (ENTA) SEC filings — annual & quarterly reports (10-K, 10-Q)
ENTA Frequently Asked Questions
Enanta Pharmaceuticals, Inc. (ENTA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Enanta Pharmaceuticals, Inc. (ENTA) reported $67.0M in revenue for fiscal year 2025. This represents a 60% increase from $41.9M in 2011.
Enanta Pharmaceuticals, Inc. (ENTA) saw revenue decline by 3.4% over the past year.
Enanta Pharmaceuticals, Inc. (ENTA) reported a net loss of $71.5M for fiscal year 2025.
Dividend & Returns
Enanta Pharmaceuticals, Inc. (ENTA) has a return on equity (ROE) of -84.6%. Negative ROE indicates the company is unprofitable.
Enanta Pharmaceuticals, Inc. (ENTA) had negative free cash flow of $18.5M in fiscal year 2025, likely due to heavy capital investments.
Explore More ENTA
Enanta Pharmaceuticals, Inc. (ENTA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates